REGN vs REX · P/E 14, rev $14.34B vs P/E 15, rev $642.5M
Regeneron Pharmaceuticals Inc (REGN) versus REX American Resources Corporation (REX) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
REX American Resources Corporation (REX) is a chemicals company listed on NYSE.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported REX revenue for 2025-01-31 was $642.5M. Net income was $71.5M. Revenue was down 22.9% from 2024-01-31 to 2025-01-31. REX currently screens at market cap $1.43B and trailing P/E 15.5.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. REX currently screens at market cap $1.43B and trailing P/E 15.5.
Not investment advice. Open the REGN and REX stock pages for the full models.
Not investment advice.